Across TCGA pan-cancer cohorts, SLC35A1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC35A1 data layer compared with 30 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SLC35A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC35A1 expression acts as an unfavorable survival marker.
CESC and UCEC are the cancer types where SLC35A1 Mutation most reproducibly stratifies survival.